Genomics: A preview of genomic medicine

BJU International

Volumn 102, Issue 9B, 2008, Pages 1221-1227

  Karam, Jose A ^a   Shariat, Shahrokh F ^a   Hsieh, Jer Tsong ^a   Knowles, Margaret A ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BCL2 RELATED PROTEIN A1; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 3; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P53; RAS PROTEIN; RETINOBLASTOMA PROTEIN; SURVIVIN; VASCULOTROPIN;

APOPTOSIS; BLADDER CARCINOMA; CANCER GENETICS; CELL CYCLE REGULATION; EPIGENETICS; HUMAN; PRIORITY JOURNAL; REVIEW; TRANSITIONAL CELL CARCINOMA;

CARCINOMA, TRANSITIONAL CELL; GENE THERAPY; GENOMICS; HUMANS; URINARY BLADDER NEOPLASMS;

EID: 54049106888     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2008.07963.x     Document Type: Review

References (106)

1. Blaveri E, Brewer JL, Roydasgupta R et al. Bladder cancer stage and outcome by array-based comparative genomic hybridization. Clin Cancer Res 2005 11 : 7012
2. Richter J, Beffa L, Wagner U et al. Patterns of chromosomal imbalances in advanced urinary bladder cancer detected by comparative genomic hybridization. Am J Pathol 1998 153 : 1615 21
3. Richter J, Jiang F, Gorog JP et al. Marked genetic differences between stage pTa and stage pT1 papillary bladder cancer detected by comparative genomic hybridization. Cancer Res 1997 57 : 2860 4
4. Veltman JA, Fridlyand J, Pejavar S et al. Array-based comparative genomic hybridization for genome-wide screening of DNA copy number in bladder tumors. Cancer Res 2003 63 : 2872 80
5. Vieten L, Belair CD, Savelieva L et al. Minimal deletion of 3p13 - >14.2 associated with immortalization of human uroepithelial cells. Genes Chromosomes Cancer 1998 21 : 39 48
6. Habuchi T, Ogawa O, Kakehi Y et al. Accumulated allelic losses in the development of invasive urothelial cancer. Int J Cancer 1993 53 : 579 84
7. Bulashevska S, Szakacs O, Brors B, Eils R, Kovacs G. Pathways of urothelial cancer progression suggested by Bayesian network analysis of allelotyping data. Int J Cancer 2004 110 : 850 6
8. Chan MW, Chan LW, Tang NL et al. Frequent hypermethylation of promoter region of RASSF1A in tumor tissues and voided urine of urinary bladder cancer patients. Int J Cancer 2003 104 : 611 6
9. Ishii H, Dumon KR, Vecchione A et al. Effect of adenoviral transduction of the fragile histidine triad gene into esophageal cancer cells. Cancer Res 2001 61 : 1578 84
10. Ishii H, Zanesi N, Vecchione A et al. Regression of upper gastric cancer in mice by FHIT gene delivery. FASEB J 2003 17 : 1768 70
11. Gibas Z, Prout GR Connolly JG, Pontes JE, Sandberg AA. Nonrandom chromosomal changes in transitional cell carcinoma of the bladder. Cancer Res 1984 44 : 1257 64
12. Gibas Z, Prout GR, Pontes JE, Connolly JG, Sandberg AA. A possible specific chromosome change in transitional cell carcinoma of the bladder. Cancer Genet Cytogenet 1986 19 : 229 38
13. Bohm M, Kirch H, Otto T, Rubben H, Wieland I. Deletion analysis at the DEL-27, APC and MTS1 loci in bladder cancer: LOH at the DEL-27 locus on 5p13-12 is a prognostic marker of tumor progression. Int J Cancer 1997 74 : 291 5
14. Bohm M, Wieland I, Schmidt C, Rubben H, Allhoff EP. Loss of heterozygosity on chromosome 5p13-12 predicts adverse prognosis in advanced bladder cancer independent of tumor stage and grade. J Urol 2002 168 : 2655 8
15. Mok SC, Chan WY, Wong KK et al. DOC-2, a candidate tumor suppressor gene in human epithelial ovarian cancer. Oncogene 1998 16 : 2381 7
16. Albertsen HM, Smith SA, Melis R et al. Sequence, genomic structure, and chromosomal assignment of human DOC-2. Genomics 1996 33 : 207 13
17. Karam JA, Shariat SF, Huang HY et al. Decreased DOC-2/DAB2 expression in urothelial carcinoma of the bladder. Clin Cancer Res 2007 13 : 4400 6
18. Adams J, Williams SV, Aveyard JS, Knowles MA. Loss of heterozygosity analysis and DNA copy number measurement on 8p in bladder cancer reveals two mechanisms of allelic loss. Cancer Res 2005 65 : 66 75
19. Takle LA, Knowles MA. Deletion mapping implicates two tumor suppressor genes on chromosome 8p in the development of bladder cancer. Oncogene 1996 12 : 1083 7
20. Wagner U, Bubendorf L, Gasser TC et al. Chromosome 8p deletions are associated with invasive tumor growth in urinary bladder cancer. Am J Pathol 1997 151 : 753 9
21. Choi C, Kim MH, Juhng SW, Oh BR. Loss of heterozygosity at chromosome segments 8p22 and 8p11.2-21.1 in transitional-cell carcinoma of the urinary bladder [In Process Citation]. Int J Cancer 2000 86 : 501 5
22. Muscheck M, Sukosd F, Pesti T, Kovacs G. High density deletion mapping of bladder cancer localizes the putative tumor suppressor gene between loci D8S504 and D8S264 at chromosome 8p233. Lab Invest 2000 80 : 1089 93
23. Stoehr R, Wissmann C, Suzuki H et al. Deletions of chromosome 8p and loss of sFRP1 expression are progression markers of papillary bladder cancer. Lab Invest 2004 84 : 465 78
24. Ohgaki K, Iida A, Ogawa O, Kubota Y, Akimoto M, Emi M. Localization of tumor suppressor gene associated with distant metastasis of urinary bladder cancer to a 1-Mb interval on 8p22. Genes Chromosomes Cancer 1999 25 : 1 5
25. Adams J, Cuthbert-Heavens D, Bass S, Knowles MA. Infrequent mutation of TRAIL receptor 2 (TRAIL-R2/DR5) in transitional cell carcinoma of the bladder with 8p21 loss of heterozygosity. Cancer Lett 2005 220 : 137 44
26. Eydmann ME, Knowles MA. Mutation analysis of 8p genes POLB and PPP2CB in bladder cancer. Cancer Genet Cytogenetics 1997 93 : 167 71
27. Knowles MA, Aveyard JS, Taylor CF, Harnden P, Bass S. Mutation analysis of the 8p candidate tumour suppressor genes DBC2 (RHOBTB2) and LZTS1 in bladder cancer. Cancer Lett 2005 225 : 121 30
28. Cairns P, Shaw ME, Knowles MA. Initiation of bladder cancer may involve deletion of a tumour-suppressor gene on chromosome 9. Oncogene 1993 8 : 1083 5
29. Obermann EC, Junker K, Stoehr R et al. Frequent genetic alterations in flat urothelial hyperplasias and concomitant papillary bladder cancer as detected by CGH, LOH, and FISH analyses. J Pathol 2003 199 : 50 7
30. van Oers JM, Adam C, Denzinger S et al. Chromosome 9 deletions are more frequent than FGFR3 mutations in flat urothelial hyperplasias of the bladder. Int J Cancer 2006 119 : 1212 5
31. Orlow I, Lacombe L, Hannon GJ et al. Deletion of the p16 and p15 genes in human bladder tumors. J Natl Cancer Inst 1995 87 : 1524 9
32. Williamson MP, Elder PA, Shaw ME, Devlin J, Knowles MA. p16 (CDKN2) is a major deletion target at 9p21 in bladder cancer. Hum Mol Genet 1995 4 : 1569 77
33. Cairns P, Polascik TJ, Eby Y et al. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet 1995 11 : 210 2
34. Knowles MA, Habuchi T, Kennedy W, Cuthbert-Heavens D. Mutation spectrum of the 9q34 tuberous sclerosis gene TSC1 in transitional cell carcinoma of the bladder. Cancer Res 2003 63 : 7652 6
35. Edwards J, Duncan P, Going JJ, Watters AD, Grigor KM, Bartlett JM. Identification of loci associated with putative recurrence genes in transitional cell carcinoma of the urinary bladder. J Pathol 2002 196 : 380 5
36. Chapman EJ, Harnden P, Chambers P, Johnston C, Knowles MA. Comprehensive analysis of CDKN2A status in microdissected urothelial cell carcinoma reveals potential haploinsufficiency, a high frequency of homozygous co-deletion and associations with clinical phenotype. Clin Cancer Res 2005 11 : 5740 7
37. Fujimoto K, Yamada Y, Okajima E et al. Frequent association of p53 gene mutation in invasive bladder cancer. Cancer Res 1992 52 : 1393 8
38. Cairns P, Proctor AJ, Knowles MA. Loss of heterozygosity at the RB locus is frequent and correlates with muscle invasion in bladder carcinoma. Oncogene 1991 6 : 2305 9
39. Cordon-Cardo C, Wartinger D, Petrylak D et al. Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer. J Natl Cancer Inst 1992 84 : 1251 6
40. Logothetis CJ, Xu H-J, Ro JY et al. Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer. J Natl Cancer Inst 1992 84 : 1256 61
41. Xu HJ, Cairns P, Hu SX, Knowles MA, Benedict WF. Loss of RB protein expression in primary bladder cancer correlates with loss of heterozygosity at the RB locus and tumor progression. Int J Cancer 1993 53 : 781 4
42. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003 349 : 2042 54
43. Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21. 3 Nat Genet 2000 25 : 315 9
44. Lee MG, Kim HY, Byun DS et al. Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma. Cancer Res 2001 61 : 6688 92
45. Maruyama R, Toyooka S, Toyooka KO et al. Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res 2001 61 : 8659 63
46. Catto JW, Azzouzi AR, Rehman I et al. Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. J Clin Oncol 2005 23 : 2903 10
47. Kawamoto K, Enokida H, Gotanda T et al. p16INK4a and p14ARF methylation as a potential biomarker for human bladder cancer. Biochem Biophys Res Commun 2006 339 : 790 6
48. Mahdy E, Pan Y, Wang N, Malmstrom PU, Ekman P, Bergerheim U. Chromosome 8 numerical aberration and C-MYC copy number gain in bladder cancer are linked to stage and grade. Anticancer Res 2001 21 : 3167 73
49. Sauter G, Carroll P, Moch H et al. c-myc copy number gains in bladder cancer detected by fluorescence in situ hybridization. Am J Pathol 1995 146 : 1131 9
50. Schmitz-Drager BJ, Schulz WA, Jurgens B et al. c-myc in bladder cancer. Clinical findings and analysis of mechanism. Urol Res 1997 25 : S45 9
51. Bruch J, Wohr G, Hautmann R et al. Chromosomal changes during progression of transitional cell carcinoma of the bladder and delineation of the amplified interval on chromosome arm 8q. Genes Chromosomes Cancer 1998 23 : 167 74
52. Olsson AY, Feber A, Edwards S et al. Role of E2F3 expression in modulating cellular proliferation rate in human bladder and prostate cancer cells. Oncogene 2007 26 : 1028 37
53. Hurst CD, Tomlinson DC, Williams SV, Platt FM, Knowles MA. Inactivation of the Rb pathway and overexpression of both isoforms of E2F3 are obligate events in bladder tumours with 6p22 amplification. Oncogene 2007 27 : 2716 27. Nov 26 epub ahead of print
54. Oeggerli M, Schraml P, Ruiz C et al. E2F3 is the main target gene of the 6p22 amplicon with high specificity for human bladder cancer. Oncogene 2006 25 : 6538 43
55. Oeggerli M, Tomovska S, Schraml P et al. E2F3 amplification and overexpression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer. Oncogene 2004 23 : 5616 23
56. Neal DE, Marsh C, Bennett MK et al. Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours. Lancet 1985 1 : 366 8
57. Bareschino MA, Schettino C, Troiani T, Martinelli E, Morgillo F, Ciardiello F. Erlotinib in cancer treatment. Ann Oncol 2007 18 (Suppl. 6 vi35 41
58. Villares GJ, Zigler M, Blehm K et al. Targeting EGFR in bladder cancer. World J Urol 2007 25 : 573 9
59. Maclaine NJ, Wood MD, Holder JC, Rees RW, Southgate J. Sensitivity of normal, paramalignant, and malignant human urothelial cells to inhibitors of the epidermal growth factor receptor signaling pathway. Mol Cancer Res 2008 6 : 53 63
60. Coombs LM, Pigott DA, Sweeney E et al. Amplification and over-expression of c-erbB-2 in transitional cell carcinoma of the urinary bladder. Br J Cancer 1991 63 : 601 8
61. Lonn U, Lonn S, Friberg S, Nilsson B, Silfversward C, Stenkvist B. Prognostic value of amplification of c-erb-B2 in bladder carcinoma. Clin Cancer Res 1995 1 : 1189 94
62. Jebar AH, Hurst CD, Tomlinson DC, Johnston C, Taylor CF, Knowles MA. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene 2005 24 : 5218 25
63. Billerey C, Chopin D, Aubriot-Lorton MH et al. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol 2001 158 : 1955 9
64. Cappellen D, De Oliveira C, Ricol D et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 1999 23 : 18 20
65. Kimura T, Suzuki H, Ohashi T, Asano K, Kiyota H, Eto Y. The incidence of thanatophoric dysplasia mutations in FGFR3 gene is higher in low-grade or superficial bladder carcinomas. Cancer 2001 92 : 2555 61
66. van Rhijn BW, Lurkin I, Radvanyi F, Kirkels WJ, van der Kwast TH, Zwarthoff EC. The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res 2001 61 : 1265 8
67. Lindgren D, Liedberg F, Andersson A et al. Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q. Oncogene 2006 25 : 2685 96
68. Tomlinson D, Baldo O, Harnden P, Knowles M. FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J Pathol 2007 213 : 91 8
69. Bakkar AA, Wallerand H, Radvanyi F et al. FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res 2003 63 : 8108 12
70. Lamy A, Gobet F, Laurent M et al. Molecular profiling of bladder tumors based on the detection of FGFR3 and TP53 mutations. J Urol 2006 176 : 2686 9
71. van Rhijn BW, van der Kwast TH, Vis AN et al. FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma. Cancer Res 2004 64 : 1911 4
72. Zieger K, Dyrskjot L, Wiuf C et al. Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors. Clin Cancer Res 2005 11 : 7709 19
73. van Rhijn BW, Lurkin I, Chopin DK et al. Combined microsatellite and FGFR3 mutation analysis enables a highly sensitive detection of urothelial cell carcinoma in voided urine. Clin Cancer Res 2003 9 : 257 63
74. van Rhijn BW, van der Poel HG, van der Kwast TH. Urine markers for bladder cancer surveillance: a systematic review. Eur Urol 2005 47 : 736 48
75. van Rhijn BW, Vis AN, van der Kwast TH et al. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J Clin Oncol 2003 21 : 1912 21
76. Aveyard JS, Skilleter A, Habuchi T, Knowles MA. Somatic mutation of PTEN in bladder carcinoma. Br J Cancer 1999 80 : 904 8
77. Cairns P, Evron E, Okami K et al. Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers. Oncogene 1998 16 : 3215 8
78. Wang DS, Rieger-Christ K, Latini JM et al. Molecular analysis of PTEN and MXI1 in primary bladder carcinoma. Int J Cancer 2000 88 : 620 5
79. Lopez-Knowles E, Hernandez S, Malats N et al. PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors. Cancer Res 2006 66 : 7401 4
80. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006 7 : 606 19
81. Fan QW, Knight ZA, Goldenberg DD et al. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 2006 9 : 341 9
82. Raynaud FI, Eccles S, Clarke PA et al. Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res 2007 67 : 5840 50
83. Olofsson B, Pajusola K, Kaipainen A et al. Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc Natl Acad Sci USA 1996 93 : 2576 81
84. Zu X, Tang Z, Li Y, Gao N, Ding J, Qi L. Vascular endothelial growth factor-C expression in bladder transitional cell cancer and its relationship to lymph node metastasis. BJU Int 2006 98 : 1090 3
85. Miyata Y, Kanda S, Ohba K et al. Lymphangiogenesis and angiogenesis in bladder cancer: prognostic implications and regulation by vascular endothelial growth factors-A-C, and -D. Clin Cancer Res 2006 12 : 800 6
86. Kowanetz M, Ferrara N. Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin Cancer Res 2006 12 : 5018 22
87. Shariat SF, Tokunaga H, Zhou J et al. p53, 21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol 2004 22 : 1014 24
88. Chatterjee SJ, Datar R, Youssefzadeh D et al. Combined effects of p53, 21, and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol 2004 22 : 1007 13
89. Malats N, Bustos A, Nascimento CM et al. P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol 2005 6 : 678 86
90. Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y. Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma. J Urol 2007 177 : 481 7
91. Shariat SF, Zlotta AR, Ashfaq R, Sagalowsky AI, Lotan Y. Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness. Mod Pathol 2007 20 : 445 59
92. George B, Datar RH, Wu L et al. p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer. J Clin Oncol 2007 25 : 5352 8
93. Stern MC, Conway K, Li Y, Mistry K, Taylor JA. DNA repair gene polymorphisms and probability of p53 mutation in bladder cancer. Mol Carcinog 2006 45 : 715 9
94. Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y. Correlation of cyclin D1 and E1 expression with bladder cancer presence, invasion, progression, and metastasis. Hum Pathol 2006 37 : 1568 76
95. Yurakh AO, Ramos D, Calabuig- Farinas S et al. Molecular and immunohistochemical analysis of the prognostic value of cell-cycle regulators in urothelial neoplasms of the bladder. Eur Urol 2006 50 : 506 15
96. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000 100 : 57 70
97. Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 1997 275 : 1132 6
98. Karam JA, Lotan Y, Karakiewicz PI et al. Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol 2007 8 : 128 36
99. Kong G, Shin KY, Oh YH et al. Bcl-2 and p53 expressions in invasive bladder cancers. Acta Oncol 1998 37 : 715 20
100. Letai AG. Diagnosing and exploiting cancer's addiction to blocks in apoptosis. Nat Rev Cancer 2008 8 : 121 32
101. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997 3 : 917 21
102. Smith SD, Wheeler MA, Plescia J, Colberg JW, Weiss RM, Alterieri DC. Urine detection of survivin and diagnosis of bladder cancer. JAMA 2001 285 : 324 8
103. Shariat SF, Casella R, Khoddami SM et al. Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. J Urol 2004 171 : 626 30
104. Shariat SF, Ashfaq R, Karakiewicz PI, Saeedi O, Sagalowsky AI, Lotan Y. Survivin expression is associated with bladder cancer presence, stage, progression, and mortality. Cancer 2007 109 : 1106 13
105. Sharp JD, Hausladen DA, Maher MG, Wheeler MA, Altieri DC, Weiss RM. Bladder cancer detection with urinary survivin, an inhibitor of apoptosis. Front Biosci 2002 7 : e36 41
106. Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 2008 8 : 61 70